BRIEF-Merus And Halozyme enter global collaboration and license agreement to develop subcutaneous formulation Of Petosemtamab

Reuters11-17

Nov 17 (Reuters) - Merus NV 2GH.F:

MERUS AND HALOZYME ENTER GLOBAL COLLABORATION AND LICENSE AGREEMENT TO DEVELOP SUBCUTANEOUS FORMULATION OF PETOSEMTAMAB
MERUS NV - TO MAKE UPFRONT AND MILESTONE PAYMENTS TO HALOZYME
MERUS NV - LICENSES HALOZYME'S ENHANZE FOR PETOSEMTAMAB
MERUS NV: HALOZYME WILL ALSO BE ENTITLED TO UP TO LOW-MID SINGLE DIGIT ROYALTIES ON NET SALES OF PETOSEMTAMAB

Source text: nPn8JHt7Ja

Further company coverage: 2GH.F

((Reuters.Briefs@thomsonreuters.com;))

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2584628901?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-11-17 20:19","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2584628901","market":"fut","top_or_hot":-1,"title":"BRIEF-Merus And Halozyme enter global collaboration and license agreement to develop subcutaneous formulation Of Petosemtamab","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\"><head><title>BRIEF-Merus And Halozyme enter global collaboration and license agreement to develop subcutaneous formulation Of Petosemtamab</title></head><body><p><span>Nov 17 (Reuters)</span><span> - </span>Merus NV <span>2GH.F</span>:</p><ul><li><p>MERUS AND HALOZYME ENTER GLOBAL COLLABORATION AND LICENSE AGREEMENT TO DEVELOP SUBCUTANEOUS FORMULATION OF PETOSEMTAMAB</p></li><li><p>MERUS NV - TO MAKE UPFRONT AND MILESTONE PAYMENTS TO HALOZYME</p></li><li><p>MERUS NV - LICENSES HALOZYME'S ENHANZE FOR PETOSEMTAMAB</p></li><li><p>MERUS NV: HALOZYME WILL ALSO BE ENTITLED TO UP TO LOW-MID SINGLE DIGIT ROYALTIES ON NET SALES OF PETOSEMTAMAB</p></li></ul><p>Source text: <span>nPn8JHt7Ja</span></p><p>Further company coverage: <span>2GH.F</span></p><p> ((Reuters.Briefs@thomsonreuters.com;))</p></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>BRIEF-Merus And Halozyme enter global collaboration and license agreement to develop subcutaneous formulation Of Petosemtamab</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nBRIEF-Merus And Halozyme enter global collaboration and license agreement to develop subcutaneous formulation Of Petosemtamab\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2025-11-17 20:19</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\"><head><title>BRIEF-Merus And Halozyme enter global collaboration and license agreement to develop subcutaneous formulation Of Petosemtamab</title></head><body><p><span>Nov 17 (Reuters)</span><span> - </span>Merus NV <span>2GH.F</span>:</p><ul><li><p>MERUS AND HALOZYME ENTER GLOBAL COLLABORATION AND LICENSE AGREEMENT TO DEVELOP SUBCUTANEOUS FORMULATION OF PETOSEMTAMAB</p></li><li><p>MERUS NV - TO MAKE UPFRONT AND MILESTONE PAYMENTS TO HALOZYME</p></li><li><p>MERUS NV - LICENSES HALOZYME'S ENHANZE FOR PETOSEMTAMAB</p></li><li><p>MERUS NV: HALOZYME WILL ALSO BE ENTITLED TO UP TO LOW-MID SINGLE DIGIT ROYALTIES ON NET SALES OF PETOSEMTAMAB</p></li></ul><p>Source text: <span>nPn8JHt7Ja</span></p><p>Further company coverage: <span>2GH.F</span></p><p> ((Reuters.Briefs@thomsonreuters.com;))</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"LU0053671581.USD","symbol_name":"摩根大通美国小盘成长股 A(dist)","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251117:nTUA5SLTDQ:1","article_id":"2584628901","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2584628901","pubTimestamp":1763381984,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"BRIEF-Merus And Halozyme enter global collaboration and license agreement to develop subcutaneous formulation Of PetosemtamabNov 17  - Merus NV 2GH.F:MERUS AND HALOZYME ENTER GLOBAL COLLABORATION AND LICENSE AGREEMENT TO DEVELOP SUBCUTANEOUS FORMULATION OF PETOSEMTAMABMERUS NV - TO MAKE UPFRONT AND MILESTONE PAYMENTS TO HALOZYMEMERUS NV - LICENSES HALOZYME'S ENHANZE FOR PETOSEMTAMABMERUS NV: HALOZYME WILL ALSO BE ENTITLED TO UP TO LOW-MID SINGLE DIGIT ROYALTIES ON NET SALES OF PETOSEMTAMABSource text: nPn8JHt7JaFurther company coverage: 2GH.F ","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"LU0053671581.USD":"摩根大通美国小盘成长股 A(dist)","HALO":"奥洛兹美医疗","BK4139":"生物科技"},"translate_title":"BRIEF-Merus和Halozyme签订全球合作和许可协议，开发Petosemtamab皮下制剂","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"HALO":0.9},"content_text":"BRIEF-Merus And Halozyme enter global collaboration and license agreement to develop subcutaneous formulation Of PetosemtamabNov 17 (Reuters) - Merus NV 2GH.F:MERUS AND HALOZYME ENTER GLOBAL COLLABORATION AND LICENSE AGREEMENT TO DEVELOP SUBCUTANEOUS FORMULATION OF PETOSEMTAMABMERUS NV - TO MAKE UPFRONT AND MILESTONE PAYMENTS TO HALOZYMEMERUS NV - LICENSES HALOZYME'S ENHANZE FOR PETOSEMTAMABMERUS NV: HALOZYME WILL ALSO BE ENTITLED TO UP TO LOW-MID SINGLE DIGIT ROYALTIES ON NET SALES OF PETOSEMTAMABSource text: nPn8JHt7JaFurther company coverage: 2GH.F ((Reuters.Briefs@thomsonreuters.com;))","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"corporation","news_rank":0,"symbols":[],"gpt_button":1,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.35.12","shortVersion":"4.35.12","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2584628901","isCrawlerRequest":true}